Skip to content

Study · In vitro (cells) · 2015

3 results

Ex vivo Efficacy of Anti-Cancer Drug PNC-27 in the Treatment of Patient-Derived Epithelial Ovarian Cancer.

Sarafraz-Yazdi E, Gorelick C, Wagreich AR, Salame G, Angert M, Gartman CH, Gupta V, Bowne WB, Lee YC, Abulafia O, Pincus MR, Michl J

Annals of clinical and laboratory science1 Jan 2015Cited by 4 (Europe PMC)

PMID26663795 (opens in a new tab)PepBankPUB-26663795
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In primary ovarian cancer cultures, PNC‑27 inhibited cell growth dose-dependently, unlike PNC-29.

    In plain wordsIn cells from ovarian cancers, PNC‑27 reduced growth with increasing dose, unlike PNC-29.

    Peptide
    PNC-27
    Outcome
    DecreasePrimary ovarian cancer cell growth
    Study

    humann: not reported in source

    Primary cultures from mucinous cystadenocarcinoma and high-grade papillary serous carcinoma
    Comparator
    PNC-29
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    PNC-27 inhibits in a dose-dependent manner the growth of and is cytotoxic to human primary cancer cells that had been freshly isolated from two ovarian epithelial cancers.
    2 context sentences
    Summary · context
    The results further show that the control peptide PNC-29 has no effect on the primary cancer cells.
    Summary · context
    We established primary cultures of freshly isolated epithelial ovarian cancer cells from patients with newly diagnosed ovarian cystadenocarcinomas. Two cell lines were obtained, one from mucinous cystadenocarcinoma, and the other from high-grade papillary serous carcinoma.
  2. 02LabIn vitro (cells)Activity measurement

    In primary ovarian cancer cultures, PNC‑27 was cytotoxic, unlike PNC-29.

    In plain wordsIn cells from ovarian cancers, PNC‑27 killed cancer cells, unlike PNC-29.

    Peptide
    PNC-27
    Outcome
    IncreasePrimary ovarian cancer cytotoxicity
    Study

    humann: not reported in source

    Primary cultures from mucinous cystadenocarcinoma and high-grade papillary serous carcinoma
    Comparator
    PNC-29
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    PNC-27 inhibits in a dose-dependent manner the growth of and is cytotoxic to human primary cancer cells that had been freshly isolated from two ovarian epithelial cancers.
    2 context sentences
    Summary · context
    The results further show that the control peptide PNC-29 has no effect on the primary cancer cells.
    Summary · context
    We established primary cultures of freshly isolated epithelial ovarian cancer cells from patients with newly diagnosed ovarian cystadenocarcinomas. Two cell lines were obtained, one from mucinous cystadenocarcinoma, and the other from high-grade papillary serous carcinoma.
  3. 03LabIn vitro (cells)Activity measurement

    In established chemotherapy-resistant human ovarian cancer cell lines, PNC‑27 was cytotoxic.

    In plain wordsIn cells from established ovarian cancer lines resistant to chemotherapy, PNC‑27 killed cells.

    Peptide
    PNC-27
    Outcome
    IncreaseEstablished chemotherapy-resistant ovarian cancer cell cytotoxicity
    Study

    humann: not reported in source

    Long-established and chemotherapy-resistant human ovarian cancer cell lines
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Our results also show that PNC-27 is cytotoxic to cells from long-established and chemotherapy-resistant human ovarian cancer cell lines.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.